spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

Pharmapack Europe 2018

Pharmapack Europe 2018

7-8 February 2018
Hall 7.1, Paris Expo, Porte de Versailles, Paris.

As Europe's dedicated Pharmaceutical Packaging and Drug Delivery event, Pharmapack is the industry's go-to place to kick-off the year. Join 411 exhibitors and 5,290 attendees for 2 days of Exhibition floor, Conferences and Innovation browsing and get an update on the latest trends, developments and regulations impacting the industry.

http://www.pharmapackeurope.com/

Contact: pharmapack@ubm.com

email pharmapack@ubm.com
web www.pharmapackeurope.com/
email Hall 7.1, Paris Expo, Porte de Versailles, Paris.
 
Print this page
Send to a friend
   
spacer
Industry Events

PDA Parenteral Packaging 2019

19-20 March 2019, Hilton Molino Stucky, Venice, Italy

PDA Europe’s Conference has become a must-attend event for all professionals in the Parenteral Packaging arena. Join us in Venice in March 2019 to continue and further deepen scientific advancements and our ongoing professional discourse of latest on primary packaging technologies and business trends. This conference and the accompanying exhibition address quality of components and cont­ainers, container closure development and integrity testing as well as aspects of processing, product distribution and storage.
More info >>

Banner of DIA_Europe_Events_95 on Samedan Banner of Drug Delivery Partnership 2018_events_97 on Samedan Banner of PHPL West Coast_events_95 on Samedan

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>


News and Press Releases

Recro Gainesville Adds New Facility, Broadens Capabilities With High-Potent Processing on Deck

Gainesville, Ga., Nov. 5, 2018 (Business Wire) – Recro Gainesville has added a 24,000-square-foot facility, which includes high-potent material processing space, near its existing 97,000-square-foot contract pharmaceutical development and manufacturing plant. The company is a wholly owned subsidiary of Recro Pharma, Inc., and a leading provider of solid oral dose development and manufacturing services for the pharmaceutical industry.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement